Opitz, C. F. and Wensel, Roland and Winkler, J. and Halank, M. and Bruch, L. and Kleber, F. X. and Hoffken, G. and Anker, S. D. and Negassa, A. and Felix, S. B. and Hetzer, R. and Ewert, R. (2005) Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. EUROPEAN HEART JOURNAL, 26 (18). pp. 1895-1902. ISSN 0195-668X, 1522-9645
Full text not available from this repository. (Request a copy)Abstract
Aims To describe the long-term clinical efficacy of inhaled iloprost as first-line vasodilator mono-therapy in patients with idiopathic pulmonary arterial hypertension (IPAH). Methods and results Seventy-six IPAH patients were prospectively identified and treated with inhaled iloprost. Clinical, haemodynamic, and exercise parameters were obtained at baseline, after 3 and 12 months of therapy and yearly thereafter. Four endpoints were prospectively defined as follows: (i) death, (ii) transplantation, (iii) switch to intravenous (i.v.) therapy, or (iv) addition of or switch to other active oral therapy. During follow-up (535 +/- 61 days), 11 patients died, six were transplanted, 25 were switched to i.v. prostanoids, 16 received additional or other oral therapy, and 12 patients discontinued iloprost inhalation for other reasons. Event-free survival at 3, 12, 24, 36, 48, and 60 months was 81, 53, 29, 20, 17 and 13%, respectively. Among haemodynamic and exercise parameters, mixed venous oxygen saturation (P < 0.001), right atrial pressure (P < 0.001), and peak oxygen uptake (P=0.002) were associated with event-free survival. Conclusion In this study, only a minority of patients could be stabilized with inhaled iloprost mono-therapy during a follow-up period of up to 5 years. In the presence of multiple treatment options, chronic iloprost inhalation as mono-therapy appears to have a limited role.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PLACEBO-CONTROLLED TRIAL; PROSTACYCLIN ANALOG; VENTILATORY EFFICIENCY; AEROSOLIZED ILOPROST; DOUBLE-BLIND; EPOPROSTENOL; INFUSION; BOSENTAN; TREPROSTINIL; INHALATION; pulmonary arterial hypertension; inhaled iloprost; chronic therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Apr 2021 12:15 |
| Last Modified: | 27 Apr 2021 12:15 |
| URI: | https://pred.uni-regensburg.de/id/eprint/35676 |
Actions (login required)
 |
View Item |
